Mark Elliott Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc., filed a Form 4 on November 18, 2026, disclosing transactions in common stock and stock options executed on November 16, 2026, pursuant to a Rule 10b5-1 plan.

Key Highlights

  • Option exercise: Boulding exercised a stock option (transaction code M) for 2,812 shares of common stock at an exercise price of $25.69 per share on November 16, 2026.
  • Shares sold: A total of 2,812 shares were sold across three separate transactions on November 16, 2026, at weighted average prices of $61.39, $62.22, and $62.90 per share.
  • Remaining beneficial ownership: Following the transactions, Boulding directly held 105,272 shares of common stock.
  • Remaining options: Following the exercise, Boulding held 14,064 stock options with an exercise price of $25.69 and an expiration date of February 14, 2034.
  • 10b5-1 plan: According to the filing, all transactions were effected pursuant to a written Rule 10b5-1 plan adopted by Boulding on September 10, 2025.
  • Option grant details: The filing states the exercised option was granted on February 15, 2024, and vests over four years, with 25% vesting on February 15, 2025, and an additional 6.25% of the original shares vesting at the end of each successive three-month period thereafter, beginning May 15, 2025.

Boulding's November 16 Transactions in PTC Therapeutics Stock

According to the Form 4 filed with the SEC on November 18, 2026, Mark Elliott Boulding, identified in the filing as Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. (NASDAQ:PTCT), reported a stock option exercise and three open-market sales of common stock, all occurring on November 16, 2026. The filing indicates all transactions were made under a pre-established Rule 10b5-1 trading plan adopted September 10, 2025.

The filing reports that Boulding exercised stock options covering 2,812 shares at an exercise price of $25.69 per share, bringing his directly held common stock to 108,084 shares. He then sold 1,315 shares at a weighted average price of $61.39 (with individual trade prices ranging from $60.87 to $61.76), 1,288 shares at a weighted average price of $62.22 (with trade prices ranging from $61.89 to $62.62), and 209 shares at a weighted average price of $62.90 (with trade prices ranging from $62.90 to $63.00). After the three sales, his directly held common stock totaled 105,272 shares, according to the filing.

In Table II, the filing discloses that the exercised option, originally granted on February 15, 2024, carried a conversion price of $25.69 and an expiration date of February 14, 2034. Following the exercise, Boulding's remaining directly held stock options with that same exercise price totaled 14,064, the filing states. The filing was signed by Avraham S. Adler as Attorney-in-Fact on November 18, 2026.

What Was Disclosed

The filing disclosed a stock option exercise of 2,812 shares and the subsequent sale of those shares in three tranches by PTC Therapeutics' EVP and CLO on November 16, 2026, all conducted under a pre-established Rule 10b5-1 plan, with 105,272 common shares and 14,064 options remaining directly held afterward.